Bli medlem
Bli medlem

Du är här


Senzime: Interesting days at the Euroanesthesia 2017 meeting

Uppsala, June 8, 2017. As previously announced, Senzime AB (publ)
participated at the Euroanesthesia (ESA) 2017 meeting in Geneva
Switzerland June 3-5. ESA is the leading European Organisation for
Anaesthesia, Critical Care, Pain and Perioperative Medicine.

With over 6000 international delegates and 100 exhibitors from more
than 80 countries, Euroanesthesia is a great international platform
in anesthesia to enhance knowledge; review innovative techniques and
network with representatives of a large international audience.

Senzime participated with a booth and met with a great amount of the
clinicians visiting the meeting. We now have several potential
customer and distributors to follow up with during the upcoming

Present at the meeting was also Dr Réka Nemes from the University of
Debrecen, Department of Anesthesiology and Intensive Care, Debrecen,

"As a clinician, I am happy to educate peer fellows on the benefits of
using objective monitoring. I have used the TetraGraph during
clinical studies and find it very effective and easy to use", says
Réka Nemes, Dr at the University of Debrecen.

For further information, please contact:

Lena Söderström, CEO

Tel: +46-70-816 39 12 email:


About Senzime

Senzime develops unique patient-oriented monitoring systems that make
it possible to assess patients' biochemical and physiological
processes before, during and after surgery. The portfolio of
technologies includes bedside systems that enable automated and
continuous monitoring of life-critical substances such as glucose and
lactate in both blood and tissues, as well as systems to monitor
patients' neuromuscular function perioperatively and in the intensive
care medicine setting. The solutions are designed to ensure maximum
patient benefit, reduce complications associated with surgery and
anesthesia, and decrease health care costs. Senzime operates in
growing markets that in Europe and the United States are valued in
excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North (ticker SEZI). FNCA is Certified Adviser for Senzime.


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.